Igor Dórea Bandeira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5608857/publications.pdf

Version: 2024-02-01

759233 552781 35 725 12 26 citations g-index h-index papers 39 39 39 809 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Intravenous arketamine for treatment-resistant depression: open-label pilot study. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 577-582.	3.2	159
2	Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. Journal of Affective Disorders, 2020, 264, 527-534.	4.1	111
3	Transcranial Direct Current Stimulation in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD). Journal of Child Neurology, 2016, 31, 918-924.	1.4	87
4	Comparative study of esketamine and racemic ketamine in treatment-resistant depression. Medicine (United States), 2018, 97, e12414.	1.0	41
5	Prevalence of depression, anxiety, and substanceâ€related disorders in parents of children with cerebral palsy: a systematic review. Developmental Medicine and Child Neurology, 2020, 62, 163-168.	2.1	39
6	Impact of Transcranial Direct Current Stimulation on Reading Skills of Children and Adolescents With Dyslexia. Child Neurology Open, 2018, 5, 2329048X1879825.	1.1	27
7	Transcranial direct current stimulation in the treatment of cerebellar ataxia: A two-phase, double-blind, auto-matched, pilot study. Clinical Neurology and Neurosurgery, 2019, 182, 123-129.	1.4	23
8	Congenital Chikungunya Virus Infection after an Outbreak in Salvador, Bahia, Brazil. AJP Reports, 2016, 06, e299-e300.	0.7	21
9	Postoperative persistent chronic pain: what do we know about prevention, risk factors, and treatment. Brazilian Journal of Anesthesiology (Elsevier), 2016, 66, 505-512.	0.4	21
10	Analysis of the superior temporal gyrus as a possible biomarker in schizophrenia using voxel-based morphometry of the brain magnetic resonance imaging: a comprehensive review. CNS Spectrums, 2021, 26, 319-325.	1.2	17
11	Neuroplasticity and non-invasive brain stimulation in the developing brain. Progress in Brain Research, 2021, 264, 57-89.	1.4	17
12	Ketamine and Esketamine augmentation for suicidal ideation: A randomized, double-blinded clinical trial. General Hospital Psychiatry, 2021, 68, 97-99.	2.4	16
13	Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard Review of Psychiatry, 2022, 30, 135-145.	2.1	15
14	Suicidal behavior in individuals with amyotrophic lateral sclerosis: A systematic review. Journal of Affective Disorders, 2020, 277, 688-696.	4.1	13
15	Medical education and leadership: a call to action for Brazil's mental health system. International Journal of Medical Education, 2018, 9, 170-172.	1.2	13
16	Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatmentâ€resistant depression. Human Psychopharmacology, 2022, 37, e2836.	1.5	13
17	Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial. Journal of Psychiatric Research, 2021, 138, 576-583.	3.1	10

The effects of transcranial direct current stimulation on attention and inhibitory control of children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Medicine (United) Tj ETQq0 0 0 rgBTI/Overlocks10 Tf 50 5

#	Article	IF	CITATIONS
19	Botulinum toxin type A in the treatment of facial myotonia in Schwartz-Jampel syndrome. Muscle and Nerve, 2017, 56, E10-E11.	2.2	6
20	NMDA Antagonists and Their Role in the Management of Bipolar Disorder: a Review. Current Behavioral Neuroscience Reports, 2020, 7, 76-85.	1.3	6
21	The impact of botulinum toxin type A in the treatment of drooling in children with cerebral palsy secondary to Congenital Zika Syndrome: an observational study. Neurological Research, 2021, 43, 54-60.	1.3	6
22	<scp><i>KPTN</i></scp> gene homozygous variantâ€related syndrome in the northeast of Brazil: A case report. American Journal of Medical Genetics, Part A, 2020, 182, 762-767.	1.2	6
23	Esketamine for Unipolar Major Depression With Psychotic Features. Journal of Clinical Psychopharmacology, 2022, 42, 408-412.	1.4	6
24	Primary cutaneous nocardiosis. JDDG - Journal of the German Society of Dermatology, 2019, 17, 327-329.	0.8	4
25	Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. Trends in Psychiatry and Psychotherapy, 2021, , .	0.8	4
26	Metabolomics of Major Depressive Disorder: A Systematic Review of Clinical Studies. Cureus, 2022, 14, e23009.	0.5	4
27	<i>Letter to the Editor: / i> Antidepressant and Antisuicidal Effects of Esketamine in Adolescents with Major Depressive Disorder and Suicidal Ideation: A Case Series. Journal of Child and Adolescent Psychopharmacology, 2022, 32, 366-367.</i>	1.3	3
28	Prevalence and factors associated with depression and anxiety in people living with HTLV-1: A systematic review with meta-analysis and meta-regression. General Hospital Psychiatry, 2021, 73, 54-63.	2.4	2
29	Primäkutane Nokardiose. JDDG - Journal of the German Society of Dermatology, 2019, 17, 327-329.	0.8	0
30	P.454 Dissociative symptoms predict antidepressant response after infusion of ketamine in treatment-resistant depression. European Neuropsychopharmacology, 2019, 29, S321-S322.	0.7	0
31	Botulinum Toxin Type A in the Spasticity of Cerebral Palsy Related to Congenital Zika Syndrome: An Observational Study. Developmental Neurorehabilitation, 2021, , 1-8.	1.1	O
32	Dabigatran for the Prevention of Myocardial Injury after Orthopedic Surgery (DMINS-PRE). A Study Protocol For A Randomized, Active-Controlled, Phase II Trial. Principles and Practice of Clinical Research Journal, 2019, 5, .	0.1	0
33	P.0899 Pilot study of the neurocognitive effects of arketamine in treatment-resistant depression and bipolar depression. European Neuropsychopharmacology, 2021, 53, S660-S661.	0.7	0
34	P.0231 Antidepressant and antisuicidal effects of esketamine in adolescents with major depressive disorder and suicidal ideation: a retrospective chart review. European Neuropsychopharmacology, 2021, 53, S167-S168.	0.7	0
35	P.0711 Intravenous (R)-ketamine for bipolar depression: report of two cases. European Neuropsychopharmacology, 2021, 53, S519-S520.	0.7	0